Saquinavir , ≥98% , 127779-20-8

Synonym(s):
2-[2-Methyl-3-(trifluoromethyl)phenylamino]nicotinic acid

CAS NO.：127779-20-8

Empirical Formula: C38H50N6O5

Molecular Weight: 670.84

MDL number: MFCD00866925

EINECS: 1806241-263-5

PRODUCT Properties

• alpha: D20 -55.9° (c = 0.5 in methanol)
• Boiling point: 1015.0±65.0 °C(Predicted)
• Density: 1.211±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: DMSO : 100 mg/mL (149.07 mM; Need ultrasonic)
• form: Powder
• pka: 11.05±0.46(Predicted)
• color: White to off-white
• Water Solubility: 35.8mg/L(25 ºC)
• BCS Class: 4
• CAS DataBase Reference: 127779-20-8(CAS DataBase Reference)

Description and Uses

Saquinavir mesylate, the first HIV protease inhibitor to reach the market, was launched in the U.S.A.. It is indicated for use in combination with approved nucleoside analogs for the treatment of advanced HIV infection. Saquinavir, a transition state analog of Phe-Pro, is a very potent and competitive inhibitor of HIV-1 and HIV-2 proteases with high specificity. Saquinavir inhibits the last stage in the replication process of HIV and prevents virion maturation in both acute and chronically infected cells. Combination of saquinavir with the nucleoside analogs such as zidovudine (AZT) or/and zalcitabine which inhibit the enzyme reverse transcriptase and target at an earlier stage in the HIV replication process, shows a greater than additive effect in increase in CD4 cell counts and reduction in viral load, with the combination delaying the onset of resistance to either drug alone. Saquinavir is well tolerated alone and in combination with A n .

Antiviral (HIV protease inhibitor).

Safety

• Symbol(GHS): GHS05
• Signal word: Danger
• Hazard statements: H314
• Precautionary statements: P501-P264-P280-P303+P361+P353-P301+P330+P331-P363-P304+P340+P310-P305+P351+P338+P310-P405
• Hazardous Substances Data: 127779-20-8(Hazardous Substances Data)